Last reviewed · How we verify

Digenin — Competitive Intelligence Brief

Digenin (KAINIC ACID) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Neuroscience.

phase 2 Adenosine receptor A3, Glutamate receptor 1, Glutamate receptor 2 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Digenin (KAINIC ACID). Kainic Acid activates the Glutamate receptor ionotropic, kainate 4, leading to excitotoxicity and neuronal damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Digenin TARGET KAINIC ACID phase 2 Adenosine receptor A3, Glutamate receptor 1, Glutamate receptor 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Digenin — Competitive Intelligence Brief. https://druglandscape.com/ci/kainic-acid. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing